

Karin E Lundin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3108439/publications.pdf>

Version: 2024-02-01

33
papers

1,061
citations

471061

17
h-index

414034

32
g-index

33
all docs

33
docs citations

33
times ranked

1941
citing authors

#	ARTICLE	IF	CITATIONS
1	2'-O-(2-N-(Aminoethyl)carbamoyl)methyl Modification Allows for Lower Phosphorothioate Content in Splice-Switching Oligonucleotides with Retained Activity. <i>Nucleic Acid Therapeutics</i> , 2022, , .	2.0	4
2	Lipophilic Peptide Dendrimers for Delivery of Splice-Switching Oligonucleotides. <i>Pharmaceutics</i> , 2021, 13, 116.	2.0	5
3	Oligonucleotides Targeting DNA Repeats Downregulate <i>Huntingtin</i> Gene Expression in Huntington's Patient-Derived Neural Model System. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 443-456.	2.0	4
4	Stereoselective pH Responsive Peptide Dendrimers for siRNA Transfection. <i>Bioconjugate Chemistry</i> , 2019, 30, 2165-2182.	1.8	19
5	Chemical Development of Therapeutic Oligonucleotides. <i>Methods in Molecular Biology</i> , 2019, 2036, 3-16.	0.4	14
6	Oligonucleotide Binding to Non-B-DNA in MYC. <i>Molecules</i> , 2019, 24, 1000.	1.7	5
7	Oligonucleotide-Palladacycle Conjugates as Splice-Correcting Agents. <i>Molecules</i> , 2019, 24, 1180.	1.7	10
8	The ability of locked nucleic acid oligonucleotides to pre-structure the double helix: A molecular simulation and binding study. <i>PLoS ONE</i> , 2019, 14, e0211651.	1.1	7
9	Sugar and Polymer Excipients Enhance Uptake and Splice-Switching Activity of Peptide-Dendrimer/Lipid/Oligonucleotide Formulations. <i>Pharmaceutics</i> , 2019, 11, 666.	2.0	10
10	Lipidated Peptide Dendrimers Killing Multidrug-Resistant Bacteria. <i>Journal of the American Chemical Society</i> , 2018, 140, 423-432.	6.6	95
11	Eleven percent intact PGM3 in a severely immunodeficient patient with a novel splice-site mutation, a case report. <i>BMC Pediatrics</i> , 2018, 18, 285.	0.7	10
12	Novel peptide-dendrimer/lipid/oligonucleotide ternary complexes for efficient cellular uptake and improved splice-switching activity. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 132, 29-40.	2.0	17
13	Role of Pseudoisocytidine Tautomerization in Triplex-Forming Oligonucleotides: In Silico and in Vitro Studies. <i>ACS Omega</i> , 2017, 2, 2165-2177.	1.6	9
14	CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression. <i>Nucleic Acids Research</i> , 2017, 45, 5153-5169.	6.5	19
15	Peptide Dendrimer-Lipid Conjugates as DNA and siRNA Transfection Reagents: Role of Charge Distribution Across Generations. <i>Chimia</i> , 2017, 71, 220.	0.3	13
16	LNA effects on DNA binding and conformation: from single strand to duplex and triplex structures. <i>Scientific Reports</i> , 2017, 7, 11043.	1.6	28
17	Four Novel Splice-Switch Reporter Cell Lines: Distinct Impact of Oligonucleotide Chemistry and Delivery Vector on Biological Activity. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 381-391.	2.0	12
18	Efficient Transfection of siRNA by Peptide Dendrimer-Lipid Conjugates. <i>ChemBioChem</i> , 2016, 17, 2223-2229.	1.3	22

#	ARTICLE	IF	CITATIONS
19	Next-generation bis-locked nucleic acids with stacking linker and 2- ϵ -glycylamino-LNA show enhanced DNA invasion into supercoiled duplexes. <i>Nucleic Acids Research</i> , 2016, 44, 2007-2019.	6.5	24
20	Delivery, Effect on Cell Viability, and Plasticity of Modified Aptamer Constructs. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 183-189.	2.0	8
21	Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) gene. <i>Clinical Immunology</i> , 2015, 161, 366-372.	1.4	28
22	RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 82, 186-193.	0.9	19
23	Oligonucleotide Therapies: The Past and the Present. <i>Human Gene Therapy</i> , 2015, 26, 475-485.	1.4	220
24	Repeatable, Inducible Micro-RNA-Based Technology Tightly Controls Liver Transgene Expression. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e172.	2.3	3
25	Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e140.	2.3	28
26	Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1410-1419.e13.	1.5	160
27	Biological Activity and Biotechnological Aspects of Locked Nucleic Acids. <i>Advances in Genetics</i> , 2013, 82, 47-107.	0.8	82
28	Formulation and Delivery of Splice-Correction Antisense Oligonucleotides by Amino Acid Modified Polyethylenimine. <i>Molecular Pharmaceutics</i> , 2010, 7, 652-663.	2.3	27
29	Nanotechnology approaches for gene transfer. <i>Genetica</i> , 2009, 137, 47-56.	0.5	22
30	Biological Activity and Biotechnological Aspects of Peptide Nucleic Acid. <i>Advances in Genetics</i> , 2006, 56, 1-51.	0.8	97
31	Increased stability and specificity through combined hybridization of peptide nucleic acid (PNA) and locked nucleic acid (LNA) to supercoiled plasmids for PNA-anchored α -Bioplex β -formation. <i>New Biotechnology</i> , 2005, 22, 185-192.	2.7	17
32	Cooperative strand invasion of supercoiled plasmid DNA by mixed linear PNA and PNA β -peptide chimeras. <i>New Biotechnology</i> , 2004, 21, 51-59.	2.7	21
33	Generation of microglia specific reagents from phage displayed peptide libraries. <i>Journal of Immunological Methods</i> , 2003, 278, 235-247.	0.6	2